把癌症攔截在早期 與我們的投資者攜手共創未來 Mirxes Holding Co. Ltd. 2629.HK 作為東南亞首家在香港交易所上市的生物科技公司,我們致力於利用專有科技、綜合「端到端」能力以及緊密的合作夥伴關係,加速在主要亞太市場及其他地區的成長。我們邀請您瀏覽此頁面,查閱財務報告、公司公告和演示文稿。這些資料都突顯了我們通過早篩挽救生命和驅動長期股東價值的使命。 公告與通函 其他重要資訊 公司治理 查看更多 財務報告 查看更多 投资者演示文稿 查看更多 分析師報告 查看更多 Featured 投資者查詢 T. +65 6816 2931 E. info@mirxes.com A. 2 Tukang Innovation Grove, #09-02 JTC MedTech Hub Singapore 618305 聯繫我們 聯繫我們 A Future Without Late Diagnosis Harnessing RNA science to detect cancer early and save lives. 公告與通知 Our Technology & Solutions in the Cancer Care Continuum LUNGClear GASTROClear APEX Tissue COMPASS Tissue ID3EAL Suite Discovery Genomics Biobanking Fortitude 2.1 Fortitude Syndromic Panel ID3EAL(TM) PanoramiR MiRNA Knowledge Panel Cancer Screening GASTROClear and LUNGClear in the market, more in the pipeline. Cancer Treatment Selection APEX and COMPASS for targeted and comprehensive Next Generation Sequencing (NGS) respectively. Discovery Genomics Genomics and bioinformatics services to enhance our partners’ biological system researches. Cancer Treatment Selection APEX and COMPASS for targeted and comprehensive Next Generation Sequencing (NGS) respectively. Discovery Genomics Genomics and bioinformatics services to enhance our partners’ biological system researches. Featured